CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025 ...

Matthew Matasar, MD, discusses odronextamab and the ongoing phase 1 ELM-1 trial in patients with CD20-positive B-cell malignancies.

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.

Breast cancer and basal cell carcinoma were the most prevalent malignancies in patients with MS undergoing long-term DMT treatment.

For a while, special purpose acquisition companies were biotech’s hot ticket to the public markets. | For a while, special ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.

H.C. Wainwright downgraded Lava Therapeutics (LVTX) to Neutral from Buy with a price target of $1.50, down from $2. The company announced a ...

There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the ...

Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases. Read why I'm bullish on ALLO ...

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.